This is a preprint.
Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of Alzheimer's disease
- PMID: 38853978
- PMCID: PMC11160633
- DOI: 10.1101/2024.05.26.595168
Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of Alzheimer's disease
Update in
-
Impaired hippocampal circuit function underlying memory encoding and consolidation precede robust Aβ deposition in a mouse model of alzheimer's disease.Sci Rep. 2025 Jul 1;15(1):21957. doi: 10.1038/s41598-025-05653-2. Sci Rep. 2025. PMID: 40594747 Free PMC article.
Abstract
Current therapeutic strategies for Alzheimer's disease (AD) target amyloid-beta (Aβ) fibrils and high molecular weight protofibrils associated with plaques, but molecular cascades associated with AD may drive neural systems failure before Aβ plaque deposition in AD. Employing hippocampal electrophysiological recordings and dynamic calcium imaging across the sleep-wake cycle in a freely behaving mouse model of AD before Aβ plaques accumulated, we detected marked impairments of hippocampal systems function: In a spatial behavioral task, phase-amplitude coupling (PAC) of the hippocampal theta and gamma oscillations was impaired and place cell calcium fluctuations were hyper-synchronized with the theta oscillation. These changes were not observed in REM sleep. In subsequent slow wave sleep (SWS), place cell reactivation was reduced. These degraded neural functions underlying memory encoding and consolidation support targeting pathological processes of the pre-plaque phase of AD to treat and prevent hippocampal impairments.
Keywords: Alzheimer’s disease; amyloid-beta; electrophysiology; hippocampus; place cell; sleep.
Conflict of interest statement
Competing interests The authors declare no competing interests.
Figures
References
-
- Bloom G. S. Amyloid-β and Tau: The Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurology 71, 505–508 (2014). - PubMed
-
- van Dyck C. H. et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine 388, 9–21 (2023). - PubMed
-
- Mintun M. A. et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med 384, 1691–1704 (2021). - PubMed
-
- Budd Haeberlein S. et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis 9, 197–210 (2022). - PubMed
-
- Honig L. S. et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J Med 378, 321–330 (2018). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources